The HDAC7 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-cell leukemia line, engineered through CRISPR/Cas9-mediated gene disruption of the HDAC7 locus. This loss-of-function model enables the study of histone deacetylase 7-dependent transcriptional regulation in a human T-lymphocyte context. The polyclonal nature of the knockout cells preserves genetic diversity, offering a robust population for functional genomics and pharmacological studies without clonal selection artifacts. The product serves as a versatile tool for investigating HDAC7-mediated repression of MEF2 target genes in immune cell biology.
The Jurkat host cell line is a human CD4+ T-cell leukemia line originally established from the peripheral blood of a 14-year-old male with acute T-cell leukemia. Jurkat cells are widely employed as a model system for T-cell receptor (TCR) signaling, immune activation, and apoptosis, largely due to their capacity for robust IL-2 production and permissiveness to HIV infection. Their genetic and phenotypic characteristics make them particularly suitable for dissecting transcriptional programs that govern T-cell fate decisions, including those controlled by class IIa histone deacetylases.
HDAC7 functions as a transcriptional repressor that associates with MEF2 transcription factors (MEF2A, MEF2C, MEF2D) to silence gene expression programs involved in immune cell differentiation, survival, and inflammatory responses. In unstimulated T cells, HDAC7 is nuclear and represses MEF2 target genes such as Nur77 (NR4A1) and Bim (BCL2L11). TCR engagement triggers calcium/calmodulin-dependent signaling, activating CaMK and PKD kinases that phosphorylate HDAC7. Phosphorylated HDAC7 binds 14-3-3 proteins, leading to nuclear export and derepression of MEF2-dependent transcription. Consequently, pro-apoptotic factors like Nur77 and Bim are induced, driving T-cell apoptosis and limiting proliferation. HDAC7 also interacts with NCoR/SMRT corepressor complexes and related class IIa HDACs (HDAC4, HDAC5), forming a regulatory node that translates extracellular signals into transcriptional responses.
In Jurkat T cells, HDAC7 knockout disrupts this signaling axis, providing a powerful model to examine the consequences of constitutive MEF2 target gene expression. The loss of HDAC7-mediated repression may alter T-cell sensitivity to TCR-induced apoptosis, modify cytokine production profiles, and impact cell cycle regulation. This polyclonal knockout population is thus valuable for dissecting the role of HDAC7 in T-ALL biology, where aberrant survival and proliferation are hallmarks. Researchers can use these cells to explore HDAC7 as a potential therapeutic target in T-cell malignancies and to screen for synthetic lethal interactions that may sensitize leukemia cells to existing therapies.
Typical applications include quantitative analysis of MEF2 target gene expression via RT-qPCR and RNA-seq, assessment of apoptosis and proliferation by flow cytometry using Annexin V and CFSE staining, and investigation of HDAC7 protein interactions by co-immunoprecipitation and Western blotting. The cells are also suited for chromatin immunoprecipitation (ChIP-qPCR) to examine HDAC7 occupancy at MEF2-regulated loci, phospho-signaling analysis of the CaMK/PKD pathway, and drug sensitivity assays with HDAC inhibitors. By providing a direct loss-of-function model in a human T-cell background, the HDAC7 Knockout Jurkat Polyclonal Cells facilitate mechanistic studies of transcriptional regulation in immune cell biology and support translational research in T-cell leukemia and autoimmune disease. For additional information, please contact Ascent Research.
